Benign Prostatic Hyperplasia (BPH) is a common condition affecting aging men, characterized by prostate overgrowth, urinary irritative symptoms, and inflammation. Traditional treatments often focus on managing these symptoms, but a more targeted approach is gaining traction. Among the most promising compounds is Elocalcitol, a selective vitamin D receptor (VDR) agonist. NINGBO INNO PHARMCHEM CO.,LTD. is at the forefront of supplying such innovative pharmaceutical intermediates.

Elocalcitol, known by its CAS number 199798-84-0, functions by binding to the vitamin D receptor (VDR). This interaction modulates a wide array of biological functions, making it a powerful tool for therapeutic intervention. For BPH, Elocalcitol's multifaceted action is particularly significant. It targets the static component of BPH by inhibiting intraprostatic growth factors, which are often downstream of the androgen receptor. This action helps to reduce prostate size, a primary contributor to urinary symptoms.

Furthermore, Elocalcitol addresses the dynamic component of BPH by influencing the RhoA/ROCK pathway within prostate and bladder cells. This pathway is critical for smooth muscle contraction and can lead to urgency and frequency of urination. By modulating this pathway, Elocalcitol can help alleviate these bothersome lower urinary tract symptoms (LUTS). The elocalcitol for benign prostatic hyperplasia application is a key area of research for this compound.

Perhaps most importantly for a holistic treatment approach, Elocalcitol also tackles the inflammatory component of BPH. It targets the NF-kappaB pathway, a central regulator of inflammatory responses. By reducing inflammation within the prostate, Elocalcitol can alleviate pain and discomfort associated with BPH. The elocalcitol anti-inflammatory activity is crucial for its comprehensive therapeutic effect.

The development and availability of high-quality pharmaceutical intermediates like Elocalcitol are vital for ongoing research and eventual clinical application. NINGBO INNO PHARMCHEM CO.,LTD. plays a critical role in ensuring that researchers and pharmaceutical developers have access to reliable elocalcitol manufacturers suppliers. For those looking to buy elocalcitol online for research purposes, understanding its elocalcitol 199798-84-0 properties is essential.

In summary, Elocalcitol represents a significant advancement in the potential treatment of BPH. Its ability to act as a selective VDR agonist and address multiple facets of the condition, from prostate growth to inflammation and dynamic symptoms, positions it as a compound of considerable interest. As research continues, the role of Elocalcitol in improving men's health is becoming increasingly clear.